December 5 (SeeNews) - Bulgarian medical consumables producer Etropal [BUL:ETR] said that it generated a consolidated net profit of 224,000 levs ($124,066/114,529 euro) in the first nine months of this year, reversing a consolidated net loss of 632,000 levs in the same period of 2022.
Etropal's total revenue grew to some 7.8 million levs in the reporting period from 4.7 million levs a year ago, the company said in an interim financial statement last week.
Operating expenses also increased, reaching 7.6 million levs from 5.4 million levs in the prior-year period. Expenses for materials more than doubled year-on-year to 3.5 million levs., but were offset by lower costs of goods sold and hired services.
Based in Etropole, western Bulgaria, Etropal is part of diversified group Synthetica [BUL:SYN] and makes medical consumables used for hemodialysis.
Shares in Etropal closed at 4.80 levs in the company's most recent trading session on the Bulgarian stock exchange on Monday.
(1 euro = 1.95583 levs)